Final-Program-ATS-2023-AP.vp

WEDNESDAY • MAY 24

323

517 Predictors of Secondary Pulmonary Hypertension Admissions in Females: An Artificial Neural Network Analysis of a National Cohort in 2019/ Z.J. Gandhi, WIlkes-Barre, PA 518 Patterns of Escalation to Oral Prostacyclin Pathway Agents Among Patients With Pulmonary Arterial Hypertension on Double Oral Therapy With Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor/ Y. Tsang, Titusville, NJ 519 The Clinical Profiles Associated With Off-label Prescribing of Pulmonary Vasodilatory Therapy in Patients With Group 3 Pulmonary Hypertension: Implications for Pragmatic Clinical Trials/ S.W. Johnson, Boston, MA 520 Cellular Indices May Be Predictive of Bleeding in Patients With Acute Pulmonary Embolism/ S. Gayen, Philadelphia, PA 521 Pulmonary Hypertension: An Unexplored Risk Factor for Stroke in Patients With Atrial Fibrillation/ G. Khattar, Staten Island, NY 522 Iron Status and Red Cell Indices in the Prognosis of Pulmonary Arterial Hypertension/ J. Wilkinson, Los Angeles, CA 523 Can AI-based Pulmonary Vascular Phenotyping on Chest-CT Detect Volume Shifts in Pulmonary Arterial and Venous Blood Volume in Operable and Non-operable Chronic Thromboembolic Pulmonary Hypertension?/ K.A. Boomars, Rotterdam, Netherlands 524 Mortality and Outcomes of Pulmonary Embolism in COVID-19 Hospitalizations, a National Analysis of NIS 2020/ N. Hakobyan, Brooklyn, NY 525 Post-acute Sequelae of SARS Co-V2 and Chronic Fatigue/Myalgic Encephalitis Share Similar Pathophysiologic Mechanisms of Exercise Limitation/ S. Jothi, Tucson, AZ

601 Age-associated Differences in Non-diseased Lung Fibroblast Inflammatory and Extracellular Matrix Processes/ K.O. Nwozor, Vancouver, Canada 602 Primary Human Lung Fibroblasts Alter Collagen Fiber Structure in 3-D Lung Extracellular Matrix-derived Hydrogels in Response to a Fibrotic Microenvironment/ M. Nizamoglu, Groningen, Netherlands 603 Remodeling of Small Airways and Associated Arterial Vasculature Is a Hallmark of Idiopathic Pulmonary Fibrosis/ N. Assadinia, Vancouver, Canada 604 A Cocktail of Idiopathic Pulmonary Fibrosis Associated Soluble Factors Disrupts Epithelial Cell Differentiation/ R. Kortekaas, Groningen, Netherlands 605 Novel Organotypic Lung Triculture Technologies Paving the Way to Personalized Medicine/ P.M. Van Ry, Provo, UT 606 Effect of Local Intratracheal Therapy Using Particleized Nintedanib in a Murine Model of Pulmonary Fibrosis/ K. Suzuki, Nagano, Japan 607 Distinct Idiopathic Pulmonary Fibrosis Associated Transcriptome and Methylome Changes in Airway and Parenchymal Fibroblasts/ P. Rajasekar, Nottingham, United Kingdom 608 Potential Role of Circadian Clock Modulator in Bleomycin-induced Pulmonary Fibrosis/ C. Prasad, Kansas City, KS 609 Interleukin-1 Alpha Counteracts Transforming Growth Factor-ß1 and ß2 Signaling in Lung Extracellular Matrix Remodeling/ K. Usman, Vancouver, Canada 610 Development of Angiotensin II Type 2 Receptor Agonists ‘ATRAGs’ for Treatment of Pulmonary Fibrosis and Pulmonary Hypertension/ R. Batta, Stockholm, Sweden 611 Developing Decellularized Tissue Hydrogel as a Culture Supplement for Building a Pulmonary Fibrosis Organoid Model/ A.J. Saxton, Provo, UT 612 Endoplasmic Reticulum Stress Induces Cellular Senescence in Human Lung Fibroblasts/ M.L. Koloko Ngassie, Rochester, MN 613 An Agent-based Model of Fibrosis on Lung Architecture/ D. Casey, Burlington, VT 614 High-fat Diet Feeding Promotes More Severe and Durable Lung Fibrotic Injury in a Bleomycin-induced and Spirometry-confirmed Mouse Model of Idiopathic Pulmonary Fibrosis (IPF)/ J. Bousamaki, Hørsholm, Denmark 615 Dual High-throughput, Automated Analysis of Histomorphometric Markers of Fibrosis and Emphysema in Two Bleomycin-induced Mouse Models of Idiopatic Pulmonary Fibrosis/ C. Serdjebi, Marseille, France

BASIC • TRANSLATIONAL POSTER DISCUSSION SESSION

D29

TRANSLATIONAL RESEARCH IN IPF

8:00 a.m. - 10:00 a.m.

Walter E. Washington Convention Center Room 201 (Level 2)

Poster Viewing

8:00-8:45 8:45-10:00

Discussion

Chairing: J.E. Peabody Lever, BA, PhD, Birmingham, AL J. Joshua, MD, San Diego, CA

ATS 2023 • Washington, DC